Shares of Quidel Co. (NASDAQ:QDEL) have earned an average rating of “Buy” from the eleven analysts that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $68.00.
A number of equities analysts have commented on the company. Raymond James lowered their price objective on Quidel from $80.00 to $70.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, December 11th. Zacks Investment Research upgraded Quidel from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a research note on Tuesday. ValuEngine lowered Quidel from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. Canaccord Genuity downgraded Quidel to a “buy” rating in a report on Tuesday, December 11th. Finally, BidaskClub raised Quidel from a “hold” rating to a “buy” rating in a report on Friday, October 12th.
In other Quidel news, CEO Douglas C. Bryant sold 7,217 shares of the firm’s stock in a transaction on Wednesday, October 31st. The stock was sold at an average price of $65.10, for a total value of $469,826.70. Following the sale, the chief executive officer now owns 301,530 shares of the company’s stock, valued at approximately $19,629,603. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Douglas C. Bryant sold 18,033 shares of the firm’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $61.17, for a total value of $1,103,078.61. Following the completion of the sale, the chief executive officer now directly owns 303,058 shares in the company, valued at approximately $18,538,057.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,250 shares of company stock worth $2,495,555. Company insiders own 16.70% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in QDEL. Eagle Asset Management Inc. boosted its holdings in shares of Quidel by 225.8% during the 3rd quarter. Eagle Asset Management Inc. now owns 652,048 shares of the company’s stock valued at $42,493,000 after acquiring an additional 451,940 shares in the last quarter. Carillon Tower Advisers Inc. acquired a new stake in shares of Quidel during the 3rd quarter valued at $25,294,000. BlackRock Inc. boosted its holdings in shares of Quidel by 22.2% during the 2nd quarter. BlackRock Inc. now owns 2,188,930 shares of the company’s stock valued at $145,564,000 after acquiring an additional 396,989 shares in the last quarter. Vanguard Group Inc boosted its holdings in shares of Quidel by 5.5% during the 3rd quarter. Vanguard Group Inc now owns 2,929,387 shares of the company’s stock valued at $190,909,000 after acquiring an additional 152,702 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Quidel by 5.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,929,387 shares of the company’s stock valued at $190,909,000 after acquiring an additional 152,702 shares in the last quarter. 90.02% of the stock is currently owned by institutional investors.
Quidel stock traded up $0.14 during mid-day trading on Tuesday, reaching $52.81. 3,338 shares of the company were exchanged, compared to its average volume of 204,428. Quidel has a 12 month low of $41.50 and a 12 month high of $77.63. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.26 and a quick ratio of 0.86. The firm has a market cap of $1.99 billion, a PE ratio of -749.71, a price-to-earnings-growth ratio of 0.75 and a beta of 1.18.
Quidel (NASDAQ:QDEL) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $0.59 EPS for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.16. Quidel had a return on equity of 25.63% and a net margin of 7.26%. The firm had revenue of $117.40 million for the quarter, compared to analyst estimates of $120.09 million. During the same quarter last year, the company earned $0.17 EPS. The company’s revenue was up 130.6% on a year-over-year basis. Sell-side analysts expect that Quidel will post 2.61 earnings per share for the current fiscal year.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
See Also: Trading Penny Stocks
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.